ATE342263T1 - Salze von benzimidazol-derivaten und deren verwendung - Google Patents

Salze von benzimidazol-derivaten und deren verwendung

Info

Publication number
ATE342263T1
ATE342263T1 AT01954427T AT01954427T ATE342263T1 AT E342263 T1 ATE342263 T1 AT E342263T1 AT 01954427 T AT01954427 T AT 01954427T AT 01954427 T AT01954427 T AT 01954427T AT E342263 T1 ATE342263 T1 AT E342263T1
Authority
AT
Austria
Prior art keywords
salt
salts
benzimidazole derivatives
benzimidazole
äää3
Prior art date
Application number
AT01954427T
Other languages
English (en)
Inventor
Keiji Kamiyama
Hideo Hashimoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE342263T1 publication Critical patent/ATE342263T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01954427T 2000-08-04 2001-08-03 Salze von benzimidazol-derivaten und deren verwendung ATE342263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000236651 2000-08-04

Publications (1)

Publication Number Publication Date
ATE342263T1 true ATE342263T1 (de) 2006-11-15

Family

ID=18728661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01954427T ATE342263T1 (de) 2000-08-04 2001-08-03 Salze von benzimidazol-derivaten und deren verwendung

Country Status (8)

Country Link
US (3) US7271182B2 (de)
EP (1) EP1306375B1 (de)
JP (1) JP5412023B2 (de)
AT (1) ATE342263T1 (de)
AU (1) AU2001276721A1 (de)
CA (2) CA2775616C (de)
DE (1) DE60123800T2 (de)
WO (1) WO2002012225A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396841B2 (en) 2000-08-18 2008-07-08 Takeda Pharmaceutical Company Limited Injections
US8595055B2 (en) 2001-03-27 2013-11-26 Points.Com Apparatus and method of facilitating the exchange of points between selected entities
US20050234103A1 (en) * 2002-03-26 2005-10-20 Reddy Manne S Crystalline forms of rabeprazole sodium
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1556043A1 (de) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Amorphe form von esomeprazol-magnesiumsalz
WO2004056804A2 (en) 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
ATE508124T1 (de) * 2003-03-24 2011-05-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von amorphem rabeprazole-natrium-salz
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
CA2528993A1 (en) 2003-06-10 2004-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
EP1718303A4 (de) * 2004-02-10 2010-09-01 Santarus Inc Kombination eines protonenpumpenhemmers, puffermittels und einem nichtsteroidalen entzündungshemmenden mittel
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (de) * 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
FR2871800B1 (fr) * 2004-06-17 2006-08-25 Sidem Pharma Sa Sa Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
KR20130038949A (ko) 2004-06-24 2013-04-18 아스트라제네카 아베 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정 변형의 제조를 위한 신규한 방법
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
DE602005020462D1 (de) 2004-08-25 2010-05-20 Essentialis Inc Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
EP1889841A4 (de) * 2005-06-07 2010-04-07 Takeda Pharmaceutical Kristall eines salzes einer benzimidazolverbindung
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
US7799777B2 (en) 2006-01-05 2010-09-21 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20080177076A1 (en) * 2006-11-06 2008-07-24 Lilach Hedvanti Processes for preparing substantially pure pantoprazole magnesium
KR20100116165A (ko) * 2007-10-12 2010-10-29 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
CN101250182B (zh) * 2008-03-26 2010-09-01 江苏奥赛康药业有限公司 兰索拉唑钠
WO2010079504A2 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable r(+)-lansoprazole amine salt and a process for preparing the same
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
US9034904B2 (en) * 2009-08-19 2015-05-19 Apotex Pharmachem Inc. Forms of dexlansoprazole and processes for the preparation thereof
EP2552904A1 (de) 2010-03-31 2013-02-06 Ranbaxy Laboratories Limited Verfahren zur herstellung von dexlansoprazol
AU2011234001B2 (en) * 2010-03-31 2014-08-28 Sun Pharmaceutical Industries Limited Salts of dexlansoprazole and their preparation
CN102399212B (zh) * 2010-08-23 2014-07-16 江苏豪森医药集团有限公司 一种右兰索拉唑晶型及其制备方法
WO2012095859A1 (en) * 2011-01-12 2012-07-19 Hetero Research Foundation Polymorphs of dexlansoprazole salts
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CA2840309A1 (en) 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN102942557A (zh) * 2012-11-26 2013-02-27 北京阜康仁生物制药科技有限公司 右兰索拉唑的新药用盐
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
CN103788068B (zh) * 2014-02-26 2016-04-06 南京海融医药科技有限公司 高熔点的手性苯并咪唑类化合物钠盐、制备方法及其用途
CN105017216A (zh) * 2014-04-16 2015-11-04 天津药物研究院 右兰索拉唑晶型iii及其制备方法和用途
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP3828648B2 (ja) * 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
CA2320963A1 (en) * 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
WO2001002389A1 (en) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
AU6727700A (en) 1999-08-25 2001-03-19 Takeda Chemical Industries Ltd. Process for the preparation of optically active sulfoxide derivatives
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
KR100775802B1 (ko) 2000-04-28 2007-11-12 다케다 야쿠힌 고교 가부시키가이샤 광학 활성 술폭시드 유도체의 제조 방법
EP1897877B1 (de) * 2000-05-15 2014-09-24 Takeda Pharmaceutical Company Limited Kristallinische Formen von (R)-Lansoprazol

Also Published As

Publication number Publication date
CA2417311A1 (en) 2003-01-27
AU2001276721A1 (en) 2002-02-18
EP1306375A4 (de) 2004-03-31
US20130281704A1 (en) 2013-10-24
EP1306375B1 (de) 2006-10-11
US8809542B2 (en) 2014-08-19
DE60123800D1 (de) 2006-11-23
US20070254924A1 (en) 2007-11-01
CA2775616A1 (en) 2002-02-14
US20030181487A1 (en) 2003-09-25
JP5412023B2 (ja) 2014-02-12
JP2002114779A (ja) 2002-04-16
EP1306375A1 (de) 2003-05-02
WO2002012225A1 (en) 2002-02-14
US7271182B2 (en) 2007-09-18
CA2775616C (en) 2013-09-17
DE60123800T2 (de) 2007-10-11
CA2417311C (en) 2012-07-10

Similar Documents

Publication Publication Date Title
ATE342263T1 (de) Salze von benzimidazol-derivaten und deren verwendung
PT1191025E (pt) Cristais de lansoprazol
FI93831B (fi) Tetratsolit, jotka ovat verenpainetta alentavien yhdisteiden välituotteita
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR9900177A (pt) Inibidores de metaloprotease.
NO982606D0 (no) Naftylsubstituerte benzimidazolderivater som antikoagulanter
DK350688A (da) Middel til heling af celler og vaev
DE60036014D1 (de) Methode zur stabilisierung von benzimidazol-verbindungen
DK506587A (da) Imidderivater
BR0109542A (pt) Derivados de imidazopirina alquilados
DK454086D0 (da) Quinolinderivater og deres anvendelse
DE69903053D1 (de) Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
IL87561A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
FI842360A0 (fi) Nya 1-acetonyl-2-(fenylimino)-imidazo lidiner, deras syraadditionssalter, dessa innehaollande laekemedel och foerfarande foer deras framstaellning.
GB8405113D0 (en) N-arylpiperazine derivatives
ATE183502T1 (de) Octahydro-2-naphthalincarbonsäure-derivate, ihre herstellung und verwendung
DK0673913T3 (da) Calcium-alkalimetalcitratforbindelser samt deres anvendelse som lægemidler
ATE104270T1 (de) Glutarsaeurederivate und ihre herstellung.
SE9803280D0 (sv) Novel compounds
ES2195309T3 (es) Derivados de tetrahidrofurano.
SE9803279D0 (sv) Novel compounds
ATE260895T1 (de) Indometacin calciumsalz pentahydrat und deren herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties